Sera Prognostics’ PreTRM test reduces neonatal morbidity, mortality by 18%

Sera Prognostics announced the publication in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis, of the top-line results from the Avert Preterm Trial. Previously, Sera reported that both co-primary outcomes-reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay-met their endpoints, and the improvements in outcome with a PreTRM test-and-treat approach were statistically significant. Results from the trial indicated: an 18% reduction in severe neonatal morbidity and mortality; a 7-day reduction in mean neonatal hospital length of stay; increased average gestational age at birth before 32 weeks of 2.48 weeks; and a 28-day reduction in neonatal length of hospital stay for babies born before 32 weeks’ gestation, reducing time spent in the hospital for those at risk of earliest delivery. The manuscript also reports that neonatal morbidity and mortality and hospital and NICU length of stay were significantly reduced in the entire intent-to-treat population. The test and treat strategy was associated with a decreased odds of preterm birth and spontaneous preterm birth at various gestational ages at birth and an average NICU length of stay savings of 0.6 days per pregnancy across all pregnancies tested.